• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • EIP Pharma Initiates Neflamapimod Study americanpharmaceuticalreview
    July 10, 2019
    EIP Pharma announced the initiation of a new Phase 2 proof-of-concept study evaluating neflamapimod as a treatment for the cognitive dysfunction associated with Huntington's disease, a rare, genetically inherited disease that causes the nerve cells of ...
  • EIP Pharma Publishes Positive Alzheimer's Disease Clinical Study Data with Neflamapimod biospace
    March 08, 2018
    EIP Pharma LLC announced today that a 3-month phase 2a clinical trial showed that neflamapimod is a brain-penetrating small molecule that inhibits the intracellular enzyme p38 MAP kinase alpha (p38α)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service